News archive

Oslo, 9 October 2026 - Observe Medical ASA (the "Company" or "Observe Medical") today announces that it has received its first significant order from Portugal for its newly launched UnoMeter™ A4 Closed System bag.

Oslo, 8 October 2026 – Observe Medical ASA (OSE: OBSRV) ("the Company" or "Observe Medical") is pleased to invite investors, analysts and other stakeholders to a presentation and trading update on Tuesday, 10 November 2026.

Oslo, 30 September 2026 - Observe Medical ASA (the "Company" or "Observe Medical") today announces a repeat customer order for UnoMeter Safeti MAX, following a comprehensive customer evaluation and successful testing of the product and its unique, patented technology.

Oslo, 22 September 2026 - Observe Medical ASA (the "Company" or "Observe Medical") today announces the launch of its new website, designed to create a direct, responsive dialogue with healthcare decision-makers about UnoMeter™ Safeti™ Max, an innovative solution with the potential to deliver clear clinical and…

Reference is made to Observe Medical ASA's Interim Report H1 2026 published on August 25, 2026. Please find attached the Interim Report H1 2026, now including the Responsibility Statement. No other changes have been made to the report.

Oslo, 10 September 2026 – Observe Medical ASA (the "Company" or "Observe Medical") is pleased to announce our entry into the Philippine market after having received the first significant order of UnoMeter Safeti Plus and UnoMeter Safeti Max.

Oslo, August 25, 2026 - Observe Medical ASA ("the Company" or "Observe Medical") today publishes its financial report for the first half of 2026. Operating revenues grew 27.4% year-over-year to NOK 14.4 million, driven by increased sales volumes across the UnoMeter™ portfolio, while the gross margin improved to 29.5%.

Oslo, 20 August 2026 - Observe Medical ASA (the "Company" or "Observe Medical") is pleased to announce that an article with clinically relevant data related to the Company's UnoMeter™ Safeti™ Max has been accepted for publication by Journal of the Healthcare Infection Society (https://www.his.org.uk/): Infection…

Oslo, 26 June 2026. With reference to today's webcast, please find enclosed the presentation. Key topics: · Market penetration and expanding portfolio is driving strong growth in order intake and sales · Continued progress in India · UnoMeter Safeti Max - foundation for clinical leadership and performance - delivering…

Oslo, 10 June 2026 – Observe Medical ASA (OSE: OBSRV) (“the Company” or “Observe Medical”) is pleased to host a presentation with trading update Friday, 26 June 2026.

Oslo, 29 May 2026 The annual general meeting of Observe Medical ASA (the "Company" or "Observe Medical", Euronext Expand ticker "OBSRV") was held today, on 29 May 2026 at 10:00 hours (CEST), at Dronning Eufemias gate 16, 2nd floor, 0191 Oslo, Norway.

Oslo, 26 May 2026 – Observe Medical ASA (the "Company" or "Observe Medical") is pleased to announce that an Abstract with in vitro clinical data related to the Company’s UnoMeter™ Safeti™ Max has been accepted for presentation and publication by the International Continence Society.

Oslo, 8 May 2026 - Observe Medical ASA (OBSRV): The annual general meeting of Observe Medical ASA will be held on Friday, 29 May 2026, at 10:00 (CEST). The annual general meeting will be held at Dronning Eufemias gate 16, 2nd floor, 0191 Oslo, Norway.

Oslo, April 30, 2026 – Observe Medical ("the Company" or "Observe Medical") has today published its Annual Report for 2025. The report is attached to this notice in ESEF and PDF format and is also available on the company's website under the Investor Relations section.

Oslo, 9 April 2026 Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) has been informed that Glimt Invest AS, a close associate of Terje Bakken, Chairman of the Board and primary insider of the Company, has purchased 182,000 shares in the Company.

Oslo, 9 April 2026 Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) has today granted 250,000 share options to primary insider and CEO of the Company, Jørgen Mann.

Oslo, 25 March 2026 - Observe Medical ASA (the "Company" or "Observe Medical") announces that its journey into the strategically important Indian market has reached a new level through the signing of an exclusive distribution agreement with a leading local partner. This replaces the previously announced LOI.

Oslo, 25 March 2026. With reference to today's webcast, please find enclosed the presentation. Key topics: · 80% growth in quarterly sales LTM · Commercial launch of UnoMeter™ Safeti Max · Extended product offering to our distributors, capitalizing on the UnoMeter brand position · Sales in 46 countries · Current…

Oslo, 4 March, 2026 - Observe Medical ASA (the "Company" or "Observe Medical") announces initiatives to reduce complexity and cost to invest further in growth. Innovation Norway financing The Company has received a NOK 15 million loan from Innovation Norway.

Oslo, February 27, 2026 - Observe Medical ("the Company" or "Observe Medical") today releases its results for the second half and the full year of 2025. Highlights · Revenue growth: UnoMeter™ portfolio revenues of NOK 7.5 million in the second half, representing an increase of 69% from the same period in 2024.

Oslo, 11 February 2025 – Observe Medical ASA (the "Company" or "Observe Medical") announces entry into the Indian market with LOI signed with strong local partner and first order received.

Oslo, 19 December 2025 – Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSRV") has received a loan commitment from Innovation Norway for a loan of NOK 15 million to support the continued commercialisation of the Company’s UnoMeter™ product portfolio, and commercial preparation for the launch of…

Oslo, 12 December 2025 – Observe Medical ASA (the "Company" or "Observe Medical") announces expansion of portfolio, progress on commercial journey and in the development of UnoMeter™ Safeti™ Max. The Company is launching an extension of its portfolio of products within the category of Urological Drainage.

Oslo, 22 October 2025: Observe Medical ASA (the "Company") has been informed that Jørgen Mann, CEO and primary insider in the Company, has today purchased 30,000 shares in the Company as further specified in the attached notification form. Following the purchase, Jørgen Mann holds 870,000 shares in the Company.

Oslo, 22 October 2025: Observe Medical ASA (the "Company") has been informed that Glimt Invest AS, a close associate to Terje Bakken, chairman of the board and primary insider of the Company, has purchased 30,000 shares in the Company as further specified in the attached notification form.

Oslo, 20 October 2025 Reference is made to the announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 13 October 2025 regarding the final result of the subsequent offering in the Company, where a total of 24,000,000 new shares were subscribed and allocated at a subscription…

Oslo, 16 October 2025 Reference is made to the announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 10 October 2025 regarding the extraordinary general meeting's resolution to increase the share capital of the Company by the issuance of 20,000,000 new shares to Songa Capital…

Oslo, 14 October 2025: Observe Medical ASA (the "Company") has been informed that Glimt Invest AS, a close associate to Terje Bakken, chairman of the board and primary insider of the Company, has purchased 425,000 shares in the Company as further specified in the attached notification form.

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") regarding (i) the issuance of 20,000,000 new shares to complete the private placement at the extraordinary general meeting held on 10 October 2025 (the "Private Placement"), and (ii) the final result of the…

*Correction: The preliminary count of received subscriptions indicates that 30,159,322 Offer Shares have been subscribed for.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Oslo, 10 October 2025 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR)) on 19 September 2025, regarding notice of an extraordinary general meeting in connection with a private placement to be carried out pursuant to an investment…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Oslo, 7 October 2025. With reference to today's webcast, please find enclosed the presentation, also made available at https://observemedical.com/.

Oslo, 6 October 2025 Reference is made to the announcement by Observe Medical ASA (the "Company, OSE ticker "OBSVR") on 25 September 2025 regarding the launch of the subsequent offering of up to 24,000,000 new shares in the Company (the "Subsequent Offering").

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Oslo, 25 September 2025 – Observe Medical ASA (the "Company" or "Observe Medical") announces further progress in the Italian market.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Oslo, 19 September 2025 Reference is made to the announcement made by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSRV") on 16 September 2025, regarding the entry into of an investment agreement with Songa Capital AS (the "Investment Agreement").

Oslo, 19 September 2025 – Observe Medical ASA (OSE: OBSRV) (“the Company” or “Observe Medical”) will host a presentation with trading update Tuesday, 7 October 2025.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Oslo, 16 September 2025 at 16:05 CET Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") has today entered into an investment agreement (the "Investment Agreement") with Songa Capital AS, an investment company owned by the Blystad Group.

Oslo, September 11, 2025 – Observe Medical ("the Company" or "Observe Medical") has initiated activities in 2 additional South American markets, Brazil and Colombia, representing a combined population of approximately 260 million.

Oslo, August 22, 2025 - Observe Medical ("the Company" or "Observe Medical") today releases its results for the first half of 2025. The Company will host a presentation with a trading update Tuesday, 23 September 2025.

Oslo, August 21, 2025 – Observe Medical ("the Company" or "Observe Medical") has received additional orders from the distributor in Switzerland after several successful hospital conversions and also receives first orders from new distributor in Slovenia after hospital product evaluations.

Oslo, 22 July 2025 Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) has today granted in total 2,600,000 share options to primary insider and CEO of the Company, Jørgen Mann, and primary insider and CFO of the Company, Johan Fagerli.

Oslo, July 11, 2025 – Observe Medical (“the Company” or “Observe Medical”) is pleased to announce that it has received first orders for UnoMeter™ Safeti™ Plus from distributors covering Argentina and the seven Central American countries. This comes in addition to a previous order already received from Chile.

Oslo, 9 July Reference is made to the announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 3 July 2025, regarding the resolution by the extraordinary the general meeting to increase the Company's share capital in connection with a private placement (the "Private Placement")…

Oslo, 4 July Reference is made to the stock exchange announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 1 July 2025, regarding the board of directors' resolution to increase the share capital of the Company by the issuance of 6,000,000 new shares to Jiangsu Hongxin Medical…

Oslo, 3 July 2025 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 11 June 2025 regarding the successfully placed private placement (the "Private Placement") of 72,890,000 new shares in the Company (the "Offer Shares") at a…

Oslo, 3 July 2025 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR)) on 12 June 2025, regarding notice of an extraordinary general meeting in connection with, inter alia, a private placement (including a loan conversion to be completed…

Oslo, 1 July 2025 Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker "OBSVR") is pleased to announce the strengthening of its strategic partnership with its key manufacturing partner, Jiangsu Hongxin Medical Technology Co.

Oslo, 1 July 2025 Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker "OBSVR") is pleased to announce the strengthening of its strategic partnership with its key manufacturing partner, Jiangsu Hongxin Medical Technology Co.

Oslo, 1 July 2025 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 27 June 2025, regarding, inter alia, the resolution of the annual general meeting to reduce the Company's share capital by way of reducing the nominal value of each…

Oslo, 27 June 2025 The annual general meeting of Observe Medical ASA (the "Company" or "Observe Medical", Euronext Expand ticker "OBSRV") was held today, on 27 June 2025 at 10:00 hours (CEST), at Dronning Eufemias gate 16, 2nd floor, 0191 Oslo, Norway.

Oslo, June 24, 2025 – Observe Medical ("the Company" or "Observe Medical") is pleased to announce that UnoMeter™ Safeti™ Plus has been appointed exclusive winner of the tender in the largest region in Sweden, representing approximately 20% of the total Swedish market.

Oslo, 12 June 2025 Reference is made to the announcement made by Observe Medical ASA (the "Company" or "Observe Medical", and, together with its subsidiaries, the "Group", OSE ticker "OBSRV") on 11 June 2025, regarding the successfully placed private placement of new shares in the Company to raise gross proceeds…

Issuer name: Observe Medical ASA Ex. date: 12 June 2025 Type of corporate action: Subsequent offering/repair issue Other information: Reference is made to the stock exchange announcement published by Observe Medical ASA on 11 June 2025 with key information relating to the subsequent offering.

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL.

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Oslo, 6 June 2025 - Observe Medical ASA (OBSRV): The annual general meeting of Observe Medical ASA will be held on Friday, 27 June 2025, at 10:00 (CEST). The annual general meeting will be held at Dronning Eufemias gate 16, 2nd floor, 0191 Oslo, Norway.

Oslo, May 30, 2025 – Observe Medical ("the Company" or "Observe Medical") has today published its Annual Report for 2024. Observe Medical has today released its Annual Report 2024, including the Board of Directors report and financial statements.

Oslo, May 14, 2025 – Observe Medical ASA («Observe Medical» or the «Company») refers to the stock exchange announcement dated 25 October 2024, regarding the preliminary letter from the Norwegian Financial Supervisory Authority («NFSA» or «Finanstilsynet») on the review of the Company’s financial reporting.

Oslo, May 7, 2025 – Observe Medical ("the Company" or "Observe Medical") announces that the scheduled annual general meeting is postponed due to the delayed publication of the 2024 annual accounts. A new date for the annual general meeting will be announced as soon as the annual accounts are published.

Oslo, April 28, 2025 – Observe Medical ("the Company" or "Observe Medical") announces that the publication of its annual report for 2024 is delayed and is expected to be published no later than 30 May 2025.

Oslo, April 28, 2025 – Observe Medical ("the Company" or "Observe Medical") is happy to announce that UnoMeter™ Safeti™ Plus is now accepted by NHS to be included on the national listing for England.

Oslo, April 10[th], 2025 – Observe Medical ("the Company" or "Observe Medical") have reached agreements in principle with Convatec and Navamedic to reduce their debt position from in total NOK 82 million to NOK 41 million, with an adjusted payment plan for the remaining debt.

With reference to today's webcast, please find enclosed the presentation, also made available at https://observemedical.com/.

Oslo, 19 March 2025 – Observe Medical ASA (OSE: OBSRV) (“the Company” or “Observe Medical”) will host an investor presentation with trading update Thursday, 10 April 2025, at 10:00 CET.

Oslo, March 18, 2025 - Observe Medical ("the Company" or "Observe Medical") today releases its results and interim report for the second half and full year of 2024.

Oslo, 13 March, 2025 – Observe Medical ("the Company" or "Observe Medical") has received repeat orders and now first significant orders from the Nordic region where UnoMeter[™] Safeti[™] Plus historically has held a very dominating position.

Oslo, 6 March, 2025 – Observe Medical ("the Company" or "Observe Medical") has received a significant repeat order from the very important Italian market that in 2021 represented almost 20 mNOK of the total UnoMeter™ annual sales.

Oslo, February 28, 2025 – Observe Medical ("the Company" or "Observe Medical") has received order from the very important UK market that in 2021 represented more than 40 mNOK of the total UnoMeter™ sales.

Oslo, 4 February 2025: Board member Kathrine Elisabeth Gamborg Andreassen has informed the board of directors of Observe Medical ASA (the "Company" or "Observe Medical") that she will resign from the Company's board of directors, effective 5 February 2025, in order to focus on her responsibilities as CEO of Navamedic…

Issuer name: Observe Medical ASA Ex. date: 14 January 2025 Type of corporate action: Reverse share split Other information: Fifteen (15) old shares will give one (1) new share. After the reverse share split, the share capital is NOK 75,107,806.80 divided into 19,258,412 shares, each with a nominal value of NOK 3.90.

Date on which the corporate action was made public: 17 December 2024. Reverse split ratio: 15 old shares give 1 new share. Last day including right: 13 January 2025. Ex-date: 14 January 2025. Record date: 15 January 2025. Date of approval: 7 January 2025.

Issuer: Observe Medical ASA Previous ISIN: NO0010865009 New ISIN: NO0013457952 Date of ISIN change: 14 January 2025 This information is published in accordance with the requirements of the Continuing Obligations for companies listed on the Oslo Stock Exchange and Euronext Expand.

Date on which the corporate action was made public: 17 December 2024. Reverse split ratio: 15 old shares give 1 new share. Last day including right: 11 January 2025. Ex-date: 14 January 2025. Record date: 15 January 2025. Date of approval: 7 January 2025.

Oslo, 9 January 2025 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 7 January 2025, regarding, inter alia, the resolution of the general meeting to increase the Company's share capital by NOK 1.30, through the issue of 5 new…

Oslo, 7 January 2025 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 7 January 2025 regarding the approval by the extraordinary general meeting of a share capital increase of NOK 1.30 through the issue of 5 new shares, each with a…

Oslo, 7 January 2025 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 17 December 2024 regarding notice of an extraordinary general meeting.

Oslo, 17 December 2024 Reference is made to the announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 5 December 2024 regarding the final results of the subsequent offering in the Company and the waiver of the condition for completion of the share capital increase of NOK…

Date on which the corporate action was made public: 17 December 2024. Reverse split ratio: 15 old shares give 1 new share. Last day including right: To be decided by the board of directors (subject to approval by the extraordinary general meeting).

Oslo, 17 December 2024 An extraordinary general meeting of Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) will be held on 7 January 2025 at 10:00 (CET).

Oslo, 13 December 2024: Observe Medical ASA (the "Company") has been informed that Seed Capital AS, a company owned 50% by Eskild Endrerud board member and primary insider in the Company, has purchased 178,268 shares in the Company as further specified in the attached notification form.

Oslo, 13 December 2024 Reference is made to the announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 5 December 2024 regarding the final result of the subsequent offering in the Company, where a total of 2,303,933 new shares were subscribed and allocated at a subscription…

Oslo, 12 December 2024: Observe Medical ASA (the "Company") has been informed that Rune Nystad, CDO and primary insider in the Company, has sold 1,144,962 shares in the Company to his wholly owned investment company US Holding AS as part of a reorganization of his shareholding.

Oslo, 12 December 2024 Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) has today granted 500,000 share options to primary insider and CFO of the Company, Johan Fagerli. Each share option gives the right to purchase one share in the Company.

Oslo, 5 December 2024: Reference is made to the stock announcement published by Observe Medical ASA (the "Observe Medical") on 5 December 2024 regarding the final result of the subsequent offering and the partial conversion to shares of certain loans from Navamedic ASA ("Navamedic") to Observe Medical.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Oslo, 26 November 2024: Observe Medical ASA (the "Company") has been informed that Jørgen Mann, CEO and primary insider in the Company, has today purchased 100,000 shares in the Company as further specified in the attached notification form. Following the purchase, Jørgen Mann holds 600,000 shares in the Company.

Oslo, 26 November 2024: Observe Medical ASA (the "Company") has been informed that Terje Bakken, chairman of the board and primary insider in the Company, has today purchased 100,000 shares in the Company as further specified in the attached notification form.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Oslo, 19 November, 2024 – Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company" or "Observe Medical") on 12 November 2024, in which it inter alia was stated that the Company is in dialogue with strategic and financial partners to evaluate options to further strengthen its…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Oslo, 15 November 2024: Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 12 November 2024, in which it inter alia was stated that the Company is in dialogue with strategic and financial partners to evaluate options to further strengthen its working capital…

Oslo, November 12[th], 2024 - Observe Medical ("the Company" or "Observe Medical") has today signed the DOC (Declaration of Conformity). This marks the final step for the establishment of a high-volume manufacturing platform for the UnoMeter™ product portfolio, consisting of UnoMeter™ 500 and UnoMeter™ Safeti™ Plus.

Oslo, 26 August 2024 Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) has today granted 1,000,000 share options to primary insider and CEO of the Company, Jørgen Mann. Each share option gives the right to purchase one share in the Company.

Oslo, August 26, 2024 - Observe Medical ("the Company" or "Observe Medical") today releases its results for the first half of 2024. Business update In the first half of 2024, Observe Medical achieved growth and market expansion of the UnoMeter™ portfolio.

Oslo, August 22, 2024 - Observe Medical ("the Company" or "Observe Medical") has received its first order of UnoMeter 500 products from a distributor in South America.

Oslo, August 19, 2024 - Observe Medical ("the Company" or "Observe Medical") will release its results for the first half year 2024 on Monday, 26 Augsut 2024. The presentation will be published on NewsWeb and the Company's website at 07:00 CET on the same day.

Oslo, August 13, 2024 - Observe Medical ASA (the "Company" or "Observe Medical") announces the appointment of Jørgen Mann as its permanent Chief Executive Officer (“CEO”). Having served as interim CEO since February 2024, Mr.

Oslo, 6 August 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 17 July 2024 (the "Announcement"), regarding share lending by Ingerø Reiten Investment Company AS in connection with tranche 2 of the private placement of new…

Oslo, 5 August 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 24 June 2024, regarding the successfully placed private placement of 55,000,000 new shares in the Company (the "Offer Shares") at a subscription price of NOK 0.40…

Oslo, 29 July 2024 – Observe Medical ASA ("the Company" or "Observe Medical") today announces a non-binding Letter of Intent (“LOI”) to explore a strategic partnership with a leading American medical imaging company (the "Partner Company").

Oslo, 17 July 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 24 June 2024 regarding the successfully placed private placement of 55,000,000 new shares in the Company (the "Offer Shares") at a subscription price of NOK 0.40 per…

Oslo, 17 July 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR)) on 26 June 2024, regarding notice of an extraordinary general meeting in connection with a private placement and contemplated subsequent offering in the Company.

Oslo, 2 July 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 24 June 2024 (the "Announcement"), regarding share lending by Ingerø Reiten Investment Company AS and ELI AS(jointly the "Share Lenders")in connection with the…

Oslo, 2 July 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 24 June 2024, regarding the successfully placed private placement of 55,000,000 new shares in the Company (the "Offer Shares") at a subscription price of NOK 0.40 per…

Oslo, 26 June 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 24 June 2024, regarding the successfully placed private placement of new shares in the Company to raise gross proceeds of NOK 22 million (the "Private Placement").

OBSRV – EX. SUBSEQUENT OFFERING TODAY Issuer name: Observe Medical ASA Ex. date: 25 June 2024 Type of corporate action: Subsequent offering/repair issue Additional information: Reference is made to the stock exchange announcement published by Observe Medical ASA on 24 June 2024 with key information relating to the…

Oslo, 25 June 2024 Reference is made to the announcement made by Observe Medical ASA (the "Company" or "Observe Medical", and, together with its subsidiaries, the "Group", OSE ticker "OBSRV") yesterday, on 24 June 2024, regarding the successfully placed private placement of new shares in the Company to raise gross…

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL.

Oslo, 24 June 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) earlier today (the "Announcement"), regarding the private placement of new shares in the Company (the "Private Placement").

Oslo, 24 June 2024 Reference is made to the announcement made by Observe Medical ASA (the "Company" or "Observe Medical", and, together with its subsidiaries, the "Group", OSE ticker "OBSRV") earlier today, on 24 June 2024, regarding the successfully placed private placement of new shares in the Company to raise gross…

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL.

Oslo, 4 June 2024 – Observe Medical ASA ("the Company" or "Observe Medical") announces that it has entered into a Letter of Intent (LOI) with Sulacare AS ("Sulacare") to collaborate on the commercial launch of Sulacare's innovative and proprietary female catheterization product.

Oslo, 3 June 2024 – Observe Medical ASA ("the Company" or "Observe Medical") continues to see positive momentum in the re-adoption of its UnoMeter™ brand of medical devices into NHS and across private hospitals in the United Kingdom and Ireland.

Oslo, 31 May 2024 – Observe Medical ASA ("the Company" or "Observe Medical") announces that its subsidiary, Biim AS ("Biim"), has extended its agreement with Fresenius Medical Care ("Fresenius") for the supply of wireless pocketable ultrasound devices.

Oslo, 27 May 2024 – Observe Medical ASA ("the Company" or "Observe Medical") is pleased to announce the early launch of the UnoMeter™ Safeti Plus, a market-leading Hourly Diuresis Monitoring System with a proven track record of safety and effectiveness.

Observe Medical ASA has today, May 24, 2024, held the Annual General Meeting. All resolutions were made in accordance with the board's and the nomination committee's proposals. The minutes from the general meeting is attached hereto and will also be available at www.observemedical.com.

Oslo, May 3, 2024 – Observe Medical ASA (OBSRV): The annual general meeting of Observe Medical ASA will be held on Friday, May 24, 2024, at 10:00 (CET). The annual general meeting will be held at Haakon VIIs gt. 1, 7th floor at Reiten & CO, 0161 Oslo, Norway.

Oslo, 30 April 2024 – Observe Medical ASA ("the Company" or "Observe Medical") today announces that the Company has published its Annual Report for 2023. The Annual Report was approved by the Board of Directors on 26 April 2024.

Oslo, April 18, 2024 - Observe Medical ASA (the "Company" or "Observe Medical") announces transfer of its Nordic distribution operations to Vingmed, following a strategic review. The Company assessed the relevance of the business, originally established as a platform for testing and launching its branded products.

Oslo, March 21, 2024 - Observe Medical ASA (the "Company" or "Observe Medical") announces that Per Arne Nygård has resigned from his position as CFO in order to pursue opportunities outside of the Company.

Oslo, March 13, 2024 - Observe Medical ("the Company" or "Observe Medical") today releases its results for the full year and second half of 2023.

Oslo, March 11, 2024 - Observe Medical ASA (the "Company" or "Observe Medical") announces that the Group, via its UK distributor C&P Medical, has been awarded onto the Scottish NHS Urology Framework with Unometer[TM ]500. This is a 3 year contract until end of March 2027, effective from April 2024.

Oslo, March 6, 2024 - Observe Medical ("the Company" or "Observe Medical") will release its results for the second half and full year 2023 on Wednesday, 13 March 2024. The presentation will be published on NewsWeb and the Company's website at 07:00 CET on the same day.

Oslo, February 29, 2024 - Observe Medical ASA (the "Company" or "Observe Medical") announces today that Rune Nystad has decided to step down from his role as Chief Executive Officer (“CEO”) with immediate effect to embrace new challenges within the Company.

Oslo, February 28, 2024 - Observe Medical ("the Company" or "Observe Medical") has received the first order for its UnoMeter products from Siramo GmbH, following the strategic Letter of Intent (LOI) announced in December 2023.

Oslo, February 13, 2024 - Observe Medical ("the Company" or "Observe Medical") has received first orders for delivery of UnoMeter™ 500 products from our distributor in Ireland, Armstrong Medical.

Oslo, January 18, 2024 - Observe Medical ("the Company" or "Observe Medical") announces the expansion of its UnoMeter portfolio into the Asian market, with UnoMeter 500 orders received from Thailand and Vietnam.

Oslo, 18 January 2024: Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company" or "Observe Medical") on 12 December 2023 regarding the final results of the rights issue of minimum 69,230,770 new shares and maximum 211,538,461 new shares in the Company at a subscription…

Oslo, January 4, 2024 - Observe Medical ("the Company" or "Observe Medical") has received first order from our distributor in Portugal, Aviquímica, for delivery of UnoMeter 500 products.

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 12 December 2023 regarding the final results of the rights issue of 137,193,548 new shares in the Company ("Offer Shares"), each with a nominal value of NOK 0.26, at a subscription price of NOK 0.26 per share (the…

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") regarding the allocation of shares in the rights issue of 137,193,548 new shares in the Company (the "Offer Shares"), at a subscription price of NOK 0.26 per share (the "Rights Issue").

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") regarding the allocation of shares in the rights issue of 137,193,548 new shares in the Company (the "Offer Shares"), at a subscription price of NOK 0.26 per share (the "Rights Issue").

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 12 December 2023 regarding the final results of the rights issue (the "Rights Issue").

Oslo, 12 December 2023: Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") regarding the rights issue of minimum 69,230,770 new shares and maximum 211,538,461 new shares in the Company (the "Offer Shares"), each with a nominal value of NOK 0.26, at a subscription…

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 27 November 2023 regarding the allocation of subscription rights (the "Subscription Rights") in the rights issue ("Rights Issue") to primary insiders and close associates.

Oslo, 12 December 2023: Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") regarding the rights issue of minimum 69,230,770 new shares and maximum 211,538,461 new shares in the Company (the "Offer Shares"), each with a nominal value of NOK 0.26, at a subscription…

Oslo, 12 December 2023: Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") regarding the rights issue of minimum 69,230,770 new shares and maximum 211,538,461 new shares in the Company (the "Offer Shares"), each with a nominal value of NOK 0.26, at a subscription…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Oslo, December 12, 2023 - Observe Medical ("the Company" or "Observe Medical") is thrilled to share that the production capacity of our flagship product, UnoMeter 500, has now reached a level on par with the historical benchmarks set by Convatec.

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 27 November 2023 regarding the allocation of subscription rights (the "Subscription Rights") in the rights issue ("Rights Issue") to primary insiders and close associates.

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 27 November 2023 regarding the allocation of subscription rights (the "Subscription Rights") in the rights issue ("Rights Issue") to primary insiders and close associates.

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 27 November 2023 regarding the allocation of subscription rights (the "Subscription Rights") in the rights issue to primary insiders and close associates.

Oslo, December 8, 2023 - Observe Medical (the “Company" or "Observe Medical") is excited to announce a significant milestone in our global expansion strategy with the signing of a Letter of Intent (LOI) for distribution of the UnoMeter portfolio in the German market.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Oslo, December 6, 2023 - Observe Medical (the “Company" or "Observe Medical") has received first order for delivery of UnoMeter 500 and Abdo Pressure products from our distributor in Croatia, Stoma Medical.

Oslo, November 29, 2023 - Observe Medical (the "Company" or "Observe Medical") has received first order for delivery of UnoMeter Abdo Pressure products from our distributor in Slovakia, Unomed.

Oslo, 29 November 2023 - Observe Medical ASA (OSE: OBSRV) (the “Company" or "Observe Medical") will host a Company presentation Monday 4 December 2023, at 13:00 CET. The presentation will take place virtually on Microsoft Teams Live Event, and is hosted by SpareBank 1 Markets.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Oslo, November 28, 2023 - Observe Medical ("the Company" or "Observe Medical") announces a new order and distribution agreement with ReplantMed, our Hungarian distributor.

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 22 November 2023, regarding the extraordinary general meeting's approval of the contemplated rights issue raising gross proceeds of up to NOK 55 million (the "Rights Issue").

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Oslo, 20 November 2023: In connection with the extraordinary general meeting of Observe Medical ASA (the "Company") to be held on 22 November 2023 (the "EGM"), Terje Bakken, chairman of the board of directors of the Company, has received proxies without voting instructions for 14,966,216 shares or 27.98% of the total…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Oslo, November 13, 2023 - Observe Medical ("the Company" or "Observe Medical") is pleased to announce the signing of a Letter of Intent (LOI) for a forthcoming exclusive Nordic distribution agreement for the UnoMeter portfolio with leading Nordic distributor Vingmed.

Oslo, November 10, 2023 - Observe Medical ("the Company" or "Observe Medical") has received follow-up orders from several distributors including the Spanish distributor, BM2 Health, for delivery of UnoMeter Abdo Pressure products, with most recent follow-up orders having a value of approx. NOK 1,3 million.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Oslo, October 26, 2023 - Observe Medical ("the Company" or "Observe Medical") today announces the shipment of the first UnoMeter™ 500 products to distributors in Poland and Spain.

Oslo, October 17, 2023 - Observe Medical (OSE: OBSRV) Observe Medical ("the Company" or "Observe Medical") today announces that it has delivered 20 Biim ultrasound probes to Fresenius Medical Care in the US.

Oslo, October 3, 2023 - Observe Medical (OSE: OBSRV) announces that the Group, via its UK distributor C&P Medical, has been awarded onto the NHS Supply Chain (NHSSC) Framework with Unometer™500. This is a 4 year contract, 2 years + an option to extend for further 2 years, effective from February 2024.

Oslo, 11 September 2023 - Observe Medical ASA (the "Company" or "Observe Medical") has secured new loans with the largest shareholders totaling NOK 7.25 million (the "Loans"). The Loans will be used to finance the first instalment under the asset transfer agreement with Unomedical and running business.

Oslo, 11 September 2023 - Observe Medical ASA ("Observe Medical" or the "Company") has, through its wholly owned subsidiary Observe Medical AS ("OMAS"), signed an asset transfer agreement with Unomedical A/S and Unomedical s.r.o.

Oslo, August 25, 2023 - The Board of Directors of Observe Medical ASA has approved the unaudited group financial results for the second quarter and first half year of 2023. Please find attached the Interim Report.

Oslo, July 4, 2023 - Observe Medical ASA ("Observe Medical" or the "Company") refers to its stock exchange notices dated 14 December 2022 and 23 March 2023, concerning, among other things, its financing plans.

Oslo, 19 June 2023 – Observe Medical ASA ("the Company" or "Observe Medical") has signed a first contract with a UK customer for delivery of Unometer™ products[*]. This marks the first entry into the UK market, which historically has accounted for a large share of Unometer™ sales.

Oslo, 5 June 2023 – Observe Medical ASA (OSE: OBSRV) (“the Company” or “Observe Medical”) will host a Company presentation Tuesday, 6 June 2023, at 14:00 CEST. The presentation will take place virtually on Microsoft Teams Live Event, and is hosted by SpareBank 1 Markets.

Observe Medical ASA has today, May 26, 2023, held the Annual General Meeting. All resolutions were made in accordance with the board's and the nomination committee's proposals. The minutes from the general meeting is attached hereto and will also be available at www.observemedical.com.

Oslo, 26 May 2023 – Observe Medical ASA (the "Company" or "Observe Medical") has received initial orders from distributors for delivery of UnoMeter™ products and is expecting to ship the first units to customers in June. The total value of these initial orders is NOK 8.2 million.

Oslo, May 5, 2023 – Observe Medical ASA (OBSRV): The annual general meeting of Observe Medical ASA will be held on Friday, May 26, 2023, at 10:00 (CET). The annual general meeting will be held at Dronning Eufemias gate 16, 0191 Oslo for those attending in person. The Notice of the Annual General Meeting is attached.

Oslo, 28 April 2023 – Observe Medical ASA ("the Company" or "Observe Medical") today announces that the Company has published its Annual Report for 2022. The Annual Report was approved by the Board of Directors on 27 April 2023.

Oslo, 20 April 2023 – Observe Medical ASA ("the Company" or "Observe Medical") today announces it has informed Ferrari L., an Italian manufacturer of medical equipment, that the Company has decided to discontinue the process of acquiring Ferrari L.

Oslo, March 23, 2023 – Observe Medical ASA ("Observe Medical" or "the Company") has entered into loan agreements for its short term financing needs.

Oslo, 6 March 2023 – Observe Medical ASA (“the Company” or “Observe Medical”) has prepared an updated company presentation which can be found attached.

Oslo, 3 March 2023 – Observe Medical ASA (“the Company” or “Observe Medical”) today provides an update on the initial letters of intent (LOIs) that have been sent to distributors of the Unometer portfolio.

Oslo, March 2, 2023 - Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), a Nordic-based medtech company focused on developing and commercializing proprietary and innovative medtech products to the global market through organic growth and targeted M&A, today publishes a shareholder letter.

Observe Medical ASA: Fourth quarter 2022 results Oslo, 17 February 2023 – Observe Medical ASA (“the Company” or “Observe Medical”) today releases its results for the fourth quarter of 2022. "The year 2022 has been a transformational year for Observe Medical.

Oslo, 10 February 2023 – Observe Medical ASA (“the Company” or “Observe Medical”) will release its fourth quarter 2022 results on Friday, 17 February 2023. The presentation will be made available on NewsWeb and the Company's website at 07:00 CET on the same day.

Oslo, January 10, 2023 - Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), a Nordic-based medtech company focused on developing and commercializing proprietary and innovative medtech products to the global market through organic growth and targeted M&A, today publishes a shareholder letter.

Oslo, 10 January 2023 – Observe Medical ASA ("the Company" or "Observe Medical") announces it has appointed Jørgen Mann as the Company’s Chief Commercial Officer.

Oslo, December 15, 2022 – Observe Medical ASA ("Observe Medical" or "the Company") today announce that Rune Nystad, CEO of Observe Medical, will present at the 13th annual DNB Nordic Healthcare Conference in Oslo, Norway, today on Thursday, December 15, 2022, at 15.35 CET.

Oslo, 14 December 2022 – The Nordic medtech company Observe Medical ASA ("Observe Medical" or "the Company") is planning to issue a NOK 30-50 million bond loan in the first quarter of 2023, which is expected to be followed by a NOK 100-150 million equity issue around mid-year 2023.

Oslo, December 14, 2022 – Observe Medical ASA ("Observe Medical" or "the Company") has entered into an exclusivity agreement to negotiate an acquisition of Ferrari L. di Ferrari Pietro S.r.l. and Ferrari Luigina S.r.l.

Observe Medical ASA (the "Company") has on November 11, 2022, granted 1,000,000 share options in the Company to the group CEO, Rune Nystad. The options have been granted with an exercise price of NOK 4.5 per option share.

Oslo, 3 November 2022 – Observe Medical ASA (“the Company” or “Observe Medical”) today release its results for the third quarter of 2022.

Oslo, October 26, 2022 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical"or the "Company"), will release its third quarter 2022 results on Thursday, 3 November 2022. The presentation will be made available on NewsWeb and the Company’s website at 07:00 CET on the same day.

Oslo, October 25, 2022 - Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), a Nordic-based medtech company focused on developing and commercializing proprietary and innovative medtech products to the global market through organic growth and targeted M&A, today publishes a shareholder letter.

Observe Medical aims for a transformative acquisition to become the leading urine measurement system provider Oslo, 21 October 2022 – Observe Medical ASA ("Observe Medical" or "the Company" and together with its subsidiary "the Group") has entered into an exclusive agreement with the intention to acquire the rights to…

Oslo, 9 September 2022 – Observe Medical ASA (“the Company” or “Observe Medical”), is pleased to announce the appointment of Carsten Trygve Bøgh as Chief Technology Officer (CTO), effective 2 October 2022. Mr.

Oslo, September 5, 2022 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), a Nordic-based medtech company focused on developing and commercializing proprietary and innovative medtech products to the global market through organic growth and targeted M&A, today publishes a shareholder letter (in…

Oslo, 25 August 2022 – Observe Medical ASA (“the Company” or “Observe Medical”) today release its results for the second quarter and first half year of 2022.

Oslo, 22 August 2022 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), will release its second quarter and first half year 2022 results on Thursday, 25 August 2022. The presentation and report will be made available on NewsWeb and the Company’s website at 07:00 CET on the same day.

Observe Medical ASA has today, June 3, 2022, held the Annual General Meeting. All resolutions were made in accordance with the board's and the nomination committee's proposals. The minutes from the general meeting is attached hereto and will also be available at www.observemedical.com.

Oslo, 3 June 2022 – Observe Medical ASA (OSE: OBSRV) (“the Company” or “Observe Medical”) today releases its first quarter results for 2022. Observe Medical has made progress across its medtech platform during the quarter, preparing and strengthening it for growth.

Oslo, 2 June 2022 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical"or the "Company"), will release its first quarter results for 2022 on Friday, 3 June 2022. The presentation will be available on Newsweb and the Company’s website at 07:00 CET.

Oslo, May 13, 2022 – Observe Medical ASA (OSE:OBSRV): The annual general meeting of Observe Medical ASA will be held on Friday, June 3 2022 at 10:00 (CET). The annual general meeting will be held at Haakon VIIs gate 2, 0161 Oslo for those attending in person and via Lumi for those attending digitally.

Oslo, 29 April 2022 – Observe Medical ASA ("the Company" or "Observe Medical") today announces that the Company has published its Annual Report for 2021, which was approved by the board of directors on 28 April 2022.

Oslo, 28 April 2022 – Observe Medical ASA ("the Company" or "Observe Medical") today announces that it has delivered an additional 58 Biim ultrasound probes to Fresenius Kidney Care in the US, completing the delivery of a total of 260 ultrasound probes in the first phase of the delivery to Fresenius Kidney Care as…

Oslo, April 1, 2022 – Observe Medical ASA ("the Company" or "Observe Medical") today announces that the Sippi® Disposable Unit has received Medical Device Regulation Certification, ensuring continued market access for the unit in Europe after 2024.

Oslo, 29 March 2022 – Observe Medical ASA (“the Company” or “Observe Medical”) today releases a combined business update and interim financial results for the fourth quarter and full year 2021. Observe Medical can also report that 202 out of 260 Biim ultrasound probes have been successfully shipped.

The Board of Directors has today appointed Rune Nystad as Chief Executive Officer (CEO) of Observe Medical ASA (the “Company” or “Observe Medical”), a Nordic medtech company with global reach. He succeeds Björn Larsson, who has headed the Company since 2019.

Oslo, March 28, 2022 - Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), will be announcing its fourth quarter 2021 results on Tuesday 29 March 2022. Members of the Management team will host a presentation at Haakon VIIs gate 2 in Oslo and the event will start at 08.30 CET.

Mandatory disclosure pursuant to section 4-2 of the Norwegian Securities Trading Act by JPB AS. Reference is made to Observe Medical ASA's (the "Company") stock exchange announcement on 10 March 2022 regarding the registration of the share capital increase pertaining to the 8,171,913 new shares in the Company with the…

Oslo, 10 March 2022: Reference is made to the stock exchange announcement by Observe Medical ASA (the "Company") on 8 March 2022 regarding the Company's completion of the acquisition of Biim Ultrasound AS and the issuance of 8,171,913 new shares in the Company as partial consideration to the sellers of Biim Ultrasound…

Oslo, 8 March 2022: Observe Medical ASA (OSE: OBSRV) (the "Company" or Observe Medical") is excited to announce the completion of the acquisition of Biim Ultrasound AS ("Biim Ultrasound"), an international medical ultrasound technology company, adding another innovative product that improves patient welfare and…

7 March 2022: Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company ") on 24 February 2022, regarding the final result of the rights issue of 25,714,286 new shares in the Company (the "Offer Shares") at a subscription price of NOK 7.00 per Offer Share (the "Rights Issue").

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") on 21 February 2022, regarding the exercise of subscription rights in the rights issue by certain primary insiders and a close associate of a primary insider, and today, on 24 February 2022 regarding the final…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 9 February 2022, regarding the commencement of the subscription period in the rights issue of 25,714,286 new shares in the Company (the "Offer Shares") at a subscription price of NOK 7.00 per offer share (the…

Mandatory disclosure pursuant to section 4-2 of the Norwegian Securities Trading Act by Navamedic ASA. Reference is made to the previous stock exchange announcements from Observe Medical ASA (the "Company") announcing a fully underwritten rights issue of 25,714,286 new shares in the Company, raising gross proceeds of…

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") on 9 February 2022, regarding the commencement of the subscription period in the rights issue (the "Rights Issue") and the receipt of subscription rights in the Rights Issue by certain primary insiders and certain…

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 9 February 2022, regarding the commencement of the subscription period in the rights issue of 25,714,286 new shares in the Company (the "Offer Shares") at a subscription price of NOK 7.00 per offer share (the…

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") on 9 February 2022, regarding the commencement of the subscription period in the rights issue (the "Rights Issue") and the receipt of subscription rights in the Rights Issue by certain primary insiders and certain…

Oslo, February 21, 2022 - Observe Medical ASA (OSE: OBSRV) today announces a new order for Sippi systems, from our distributor in Poland, Skamex. Observe Medical ASA (the "Company") has today, on 21 February 2022, received an order for 30 Sippi® Base units and 300 Sippi® Disposable units from Skamex.

Mandatory disclosure pursuant to section 4-2 of the Norwegian Securities Trading Act by TopRidge Pharma (Ireland) Limited ("TopRidge Pharma").

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") earlier today, on 9 February 2022, regarding the commencement of the subscription period in the rights issue (the "Rights Issue").

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Oslo, February 7, 2022 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), a Nordic-based medtech company focused on developing and commercializing proprietary and innovative medtech products to the global market through organic growth and targeted M&A, today publishes a shareholder letter (in…

Issuer name: Observe Medical ASA Ex.date: 7 February 2022 Type of corporate action: Rights issue This information is published in accordance with the requirements of the Continuing Obligations.

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") on 14 January 2022 regarding a proposed fully underwritten rights issue in the Company (the "Rights Issue").

Reference is made to the key information relating to the preferential rights issue published by Observe Medical ASA (the "Company") on 14 January 2022.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Oslo, 2 February 2022: In connection with the extraordinary general meeting of Observe Medical ASA (the "Company") to be held on 4 February 2022 (the "EGM"), Terje Bakken, chairman of the board of directors of the Company, has as at the close of trading on the Oslo Stock Exchange on 2 February 2022, received proxies…

· Observe Medical will develop and commercialize proprietary, innovative medtech products to the global market · International distributor and partner network with a Nordic direct sales organization · The agreement is set to accelerate the global commercial roll-out of the combined portfolio, including Sippi® US…

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") earlier today, on 14 January 2022, regarding the resolution by the Company's board of directors to propose that the Company carries out a share capital increase, by way of a fully underwritten rights issue, to raise…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Oslo, November, 3rd, 2021 - Observe Medical ASA (OSE: OBSRV) today released its financial results and presentation of the third quarter of 2021.

Observe Medical ASA invites you to a presentation of the third quarter 2021. The presentation will take place at Felix Konferansesenter in Oslo on Wednesday, November 3rd.

Oslo, October 22, 2021 – Observe Medical ASA (OSE: OBSRV) continues its rollout of Sippi®, and reports clinical implementation at several sites in Europe – including use outside intensive care units, and clinical evaluations driving the health economic value of Sippi® “We are excited to see Sippi® implementation…

FINANCIAL YEAR 2021 03.11.2021 - Quarterly Presentation - Q3 17.02.2022 - Quarterly Presentation - Q4 29.04.2022 – Annual Report 02.06.2022 – Annual General Meeting FINANCIAL YEAR 2022 12.05.2022 - Quarterly Presentation - Q1 25.08.2022 – Second quarter and Half-year Report 03.11.2022 - Quarterly Report - Q3 This…

Oslo, September 27th, 2021 – Observe Medical ASA (OSE: OBSRV) continues its rollout of Sippi®, and today announces that a major regional hospital in Italy has decided to implement Sippi® in the intensive care unit (ICU), with wireless connection to the hospital’s patient data management system.

Oslo, August 20[th], 2021 – Observe Medical ASA (OSE: OBSRV) today released its financial results and presentation of the second quarter and first half-year of 2021, reporting continuous progress in the go-to-market execution for Sippi®, a unique and proprietary solution for digital, automated urine monitoring.

Observe Medical ASA invites you to a presentation of the second quarter and first half year 2021. The presentation will take place at Felix Konferansesenter in Oslo on Friday, August 20th.

Oslo June 30, 2021 – Observe Medical ASA (OSE: OBSRV), today announces that it has entered into a distribution agreement and partnership with Skamex (Poland) for the launch of Sippi® in the Polish and the Romanian market.

Observe Medical ASA has today, May 21, 2021, held the Annual General Meeting. All resolutions were made in accordance with the board's and the nomination committee's proposals. The minutes from the general meeting is attached hereto and will also be available at www.observemedical.com.

Oslo, 20 May 2021: In connection with the annual general meeting of Observe Medical ASA (the "Company") to be held on 21 May 2021 (the "AGM"), Terje Bakken, chairman of the board of directors of the Company, has as at the close of trading on the Oslo Stock Exchange on 20 May 2021, received proxies without voting…

Oslo, May 12[th], 2021 – Observe Medical ASA (OSE: OBSRV) today released its presentation of the first quarter 2021, reporting continued advancement for the commercialization and go-to-market strategy Sippi®, a unique and proprietary solution for digital automated urine monitoring in hospitals.

Observe Medical ASA invites you to a presentation of the first quarter 2021 on Wednesday May 12 at 8.30 CET. Due to the covid-19 situation the presentation will be held as a webcast only.

Oslo May 07, 2021 – Observe Medical ASA (OSE: OBSRV), announces that Nya Karolinska Sjukhuset, Sweden, prepares new studies to broaden the clinical scope of use for Sippi® automated, digital urine measurement system, building further on the results from the recent dissertation by Dr Martin Slettengren.

Oslo May 6, 2021 – Observe Medical ASA (OSE: OBSRV), announces that Sippi® automated and digital urine meter recently received new patent approvals in India, China and Brazil, further expanding and strengthening the global patent protection for Sippi® proprietary technology.

Oslo, April 30, 2021 – Observe Medical ASA (OSE:OBSRV): The annual general meeting of Observe Medical ASA will be held on Friday, May 21, 2021 at 09:00 (CET) in the Observe Medical offices in Henrik Ibsens gate 90 (3rd floor), 0255 Oslo. The Notice of the Annual General Meeting is attached.

Oslo, April 30, 2021 – Observe Medical ASA (OSE:OBSRV): Attached Observe Medical ASA`s annual report for 2020. The report is also available on the company's website, www.observemedical.com The annual report was reviewed and approved by the board of directors on April 29, 2021.

Oslo 22 March 2021 – Observe Medical ASA (OSE: OBSRV), today announces that Observe Medical Group has received a follow-up order to deliver additional quantity of safety needles to a hospital region in the Nordic market.

Oslo 8 March 2021 – Observe Medical ASA (OSE: OBSERV), today announces an order to deliver a newly introduced blood & fluid warmer system, including disposable supplies, to two university hospitals and one regional hospital in Nordic market.

Oslo, February 23[rd], 2020 – Observe Medical ASA (OSE: OBSRV) today released its presentation of the fourth quarter 2020, reporting continued progress in terms of the commercialization and go-to-market strategy for its first product Sippi®.

Observe Medical ASA invites you to a presentation of the fourth quarter 2020 on Tuesday February 23 at 8.30 CET. Due to the covid-19 situation the presentation will only be held as a webcast.

Oslo February 22, 2021 – Observe Medical ASA (OSE: OBSERV), announces that Nya Karolinska Sjukhuset in Stockholm, Sweden resumes the implementation of Sippi® in clinical use at the Cardiothoracic ICU unit following a pause during 2020, due to Covid-19 As a result of the recent improvements of the Covid-19 situation at…

Oslo February 12, 2021 – Observe Medical ASA (OSE: OBSERV), announces that a major hospital in Northern Italy has equipped the ICU department with Sippi® systems in clinical use, the result of the close collaboration with Observe Medical distributor in Italy, SIM Italia.

Oslo February 4, 2021 – Observe Medical ASA (OSE: OBSERV), announces strengthened presence in Norway through a partnership agreement with the Norwegian medtech agency Yallow Life Science AS and an enhanced collaboration with Norway Health Tech.

Oslo 29 January 2021 – Observe Medical ASA (OSE: OBSERV), today announces that Observe Medical Group has received a significant order for medical consumables from a hospital region in the Nordic market.

Observe Medical ASA, January 15, 2021 – A doctoral (PhD) dissertation at Karolinska Institute, Stockholm, Sweden, demonstrates multiple clinical benefits of the Sippi® automated digital urine meter, and the potential paradigm shift in clinical practice of urine measurement.

Observe Medical ASA, December 21, 2020: Following the acquisition by Observe Medical of Sylak AB on October 30, the team and product portfolio are now successfully integrated into Observe Medical and in full operations, with focus on the Swedish market.

Oslo, November 3rd, 2020 - Observe Medical ASA (OSE: OBSERV) today released its presentation of the third quarter 2020, reporting important steps forward in terms of the commercialization and go-to-market strategy for its first product Sippi®.

Observe Medical ASA invites you to a presentation of the third quarter 2020. The presentation will take place at Felix Konferansesenter in Oslo on Tuesday, November 3.

Observe Medical ASA, October 30, 2020: On October 29, 2020, Observe Medical announced the signing of the final agreement to acquire Sylak AB, a distributor of ICU/anaesthesia products in the Swedish market, for an enterprise value of SEK 6 million (on a cash and debt free basis).

Observe Medical ASA, October 29, 2020: Reference is made to Observe Medical’s announcement October 16, 2020 regarding the signing of a letter of intent to acquire Sylak AB, a distributor of ICU/anaesthesia products in the Swedish market, for an enterprise value of SEK 6 million (on a cash and debt free basis).

Observe Medical ASA, October 16, 2020: Observe Medical ASA (the "Company" or "Observe Medical") has signed a non-binding term sheet including an exclusive right to acquire 100% of the shares in Sylak AB (“Sylak”), a Swedish private limited company, for an agreed enterprise value of SEK 6 million (on a cash and debt…

Oslo, 4 September 2020: Reference is made to the stock exchange announcement by Observe Medical ASA (the "Company") on 31 August 2020 regarding the exercise of employee share options and issue of 171,875 new shares in the Company.

Oslo, 31 August 2020: The board of directors of Observe Medical ASA (the "Company") has resolved to increase the share capital of the Company following the completion of an exercise period for vested share options. 1.

Oslo, 18 August 2020 – Observe Medical ASA (OSE: OBSERV) today released its interim report for the second quarter and first half year of 2020. The company’s initial product, Sippi, a unique and proprietary solution for digital automated urine monitoring in hospitals is in an early stage of commercialization.

A recently published article demonstrates that the patented Sippcoat® technology, an integrated part of Sippi® system, from Observe Medical, significantly reduces microbial biofilm formation in medical devices, suggesting a new strategy for reducing hospital-acquired infections.

Observe Medical ASA invites you to a presentation of the second quarter and first half year of 2020 figures. The presentation will take place at Felix Konferansesenter in Oslo on Tuesday, August 18th.

Oslo 7 August 2020 – Observe Medical ASA (OSE: OBSERV), today announces it has entered into an updated distribution agreement and strengthened partnership with SIM Italia S.r.l. for the launch of Sippi® in the Italian market.

(Oslo, 20 July 2020) Notice of exercise of employee share options In connection with the expiry date at 31 March 2020, postponed by the Board of Directors to no later than 30 September 2020, Kathrine Gamborg Andreassen, board member, have at 20 July 2020 given notice that she will exercise a total of 125,000 options…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Reference is made to Observe Medical ASA's (the "Company") stock exchange announcement on 6 July 2020 regarding the final result in the in the rights issue of 4,090,909 new shares in the Company (the "Offer Shares") at a subscription price of NOK 11.00 per share (the "Rights Issue").

Reference is made to Observe Medical ASA's (the "Company") stock exchange announcement on 6 July 2020 regarding the final result in the in the rights issue of 4,090,909 new shares in the Company (the "Offer Shares") at a subscription price of NOK 11.00 per share (the "Rights Issue").

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Oslo, Norway, 3 July 2020. Primary Insider and CEO, Björn Larsson, has today purchased 17,000 shares in Observe Medical ASA at an average price of NOK 13.27. Following this transaction, Björn Larsson holds 17,000 shares and 120,000 options in Observe Medical ASA.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Reference is made to the ongoing rights issue of 4,090,909 new shares (the "Offer Shares") at a subscription price of NOK 11.00 per share in Observe Medical ASA (the "Company") as announced in the Company's stock exchange announcement on 19 June 2020 (the "Rights Issue").

Observe Medical ASA has today, June 30, 2020, held the Annual General Meeting. All resolutions were made in accordance with the board's and the nomination committee's proposals. The minutes from the general meeting is attached hereto and will also be available at www.observemedical.com.

Reference is made to the ongoing rights issue of 4,090,909 new shares to a subscription price of NOK 11.00 (the "Offer Shares") in Observe Medical ASA (the "Company") as announced in the Company's stock exchange announcement on 19 June 2020 (the "Rights Issue").Ingerø Reiten Investment Company AS ("IRIC"), represented…

Reference is made to the ongoing rights issue of 4,090,909 new shares to a subscription price of NOK 11.00 (the "Offer Shares") in Observe Medical ASA (the "Company") as announced in the Company's stock exchange announcement on 19 June 2020 (the "Rights Issue").

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

The annual general meeting of Observe Medical ASA (OSE: OBSERV) will be held on Tuesday, June 30 2020 at 14:00 (CET) in the Observe Medical offices in Henrik Ibsens gate 90 (3rd floor), 0255 Oslo. The Notice of the Annual General Meeting is attached.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Oslo, 12 May 2020 – Observe Medical ASA (OSE: OBSERV) today released its presentation of the first quarter 2020, including an updated market study indicating a doubling of the potential market value for the company’s first product, Sippi®.

Observe Medical ASA invites you to a presentation of the first quarter 2020 figures. The presentation will take place at Felix Konferansesenter in Oslo on Tuesday, May 12th.

Attached Observe Medical ASA`s annual report for 2019. The report is also available on the company's website, www.observemedical.com The annual report was reviewed and approved by the board of directors on 29 April 2020.

Oslo, 19 March 2020 – Observe Medical ASA (OSE: OBSERV) today provides a business update in light of COVID-19. The company reports continued high activity level in operations, and several initiatives in the launch and roll-out of Sippi®.

Observe Medical ASA, 28 February 2020: Reference is made to the stock exchange announcement by Observe Medical ASA (the "Company") on 24 January 2020 regarding the exercise of employee share options and issue of 275,000 new shares in the Company.

Oslo, 25 February 2020 – Observe Medical ASA (OSE: OBSERV) continued implementation of its growth strategy in the fourth quarter of 2019, including the commercialization of its first product Sippi®. “In the fourth quarter of 2019, we have taken important steps in the commercialization of Sippi.

Observe Medical ASA invites you to a presentation of the fourth quarter and full year 2019 figures. The presentation will take place at Felix Konferansesenter in Oslo on Tuesday, February 25th.

(Oslo, 24 January 2020) Exercise of employee share options In connection with the expiry date at 24 January three employees in Navamedic ASA have exercised a total of 275,000 options in Observe Medical ASA.

Observe Medical ASA Board of Directors has on January 9 2020, as part of a long-term incentive plan, approved granting Björn Larsson (CEO in Observe Medical ASA) 60 000 series A options and 60 000 series B options. Each option, when exercised, will give the right to acquire one share in Observe Medical ASA.

Financial calendar for Observe Medical ASA FINANCIAL YEAR 2019 17.04.2020 - Annual Report 03.06.2020 - Annual General Meeting 25.02.2020 - Quarterly Report - Q4 FINANCIAL YEAR 2020 18.08.2020 - Half-yearly Report 12.05.2020 - Quarterly Report - Q1 03.11.2020 - Quarterly Report - Q3 This information is published…

Oslo, 9 December 2019: Observe Medical ASA (“Observe Medical”) today announces that Per Arne Nygård is appointed interim Chief Financial Officer of the company for the period 9 December, 2019 to 1 March, 2020. Per Arne Nygård has been with Navamedic ASA as a consultant since August, 2019.

Observe Medical ASA, 1 November 2019: Reference is made to Navamedic ASA's ("NAVA") and Observe Medical ASA's ("Observe Medical") stock exchange announcements dated 30 October 2019 and 31 October 2019, regarding Oslo Børs' approval of Observe Medical's application for listing of its shares on Oslo Axess (the…

Observe Medical ASA, 1 November 2019: On 1 October 2019, the general meeting of Observe Medical ASA (the "Company) resolved to increase the share capital of the Company with NOK 832,000 by issuance of 3,200,000 new shares to Navamedic ASA, each with a nominal value of NOK 0.26, by way of set-off against a receivable…

Reference is made to the announcement from Navamedic ASA 31.10.2019 The shares in Navamedic ASA will today be traded exclusive of rights to consideration shares in Observe Medical ASA.

Observe Medical ASA, 31 October 2019: Reference is made to Navamedic ASA's ("NAVA") previous stock exchange announcements regarding the proposed demerger of NAVA with transfer to Observe Medical ASA (the "Company" or "Observe Medical").

Navamedic ASA, 31 October 2019: The shares in Navamedic ASA ("NAVA") will today on Thursday 31 October 2019 for the last day trade inclusive of rights to consideration shares in Observe Medical ASA ("Observe Medical") to be distributed in connection with the demerger of NAVA.

Observe Medical ASA, 30 October 2019: Reference is made to the previous stock exchange notices made by Navamedic ASA ("NAVA") on 19 June 2019 and 5 August 2019 regarding the demerger of NAVA, whereby inter alia NAVA's Medtech division is demerged from NAVA and merged into Observe Medical ASA (the "Company" or "Observe…

Oslo Børs has resolved to admit the shares in Observe Medical ASA to listing on Oslo Axess. It is stipulated that the company prior to the first day of listing must satisfy the listing requirements on Oslo Axess.

Observe Medical ASA: New CEO appointed and board authorisation to increase the share capital of the company proposed by the board and approved by the extraordinary general meeting.

Oslo Børs has received a request for admission to trading from Observe Medical ASA on Oslo Axess. The disclosure of information requirement set out in sections 5-1, 5-2 and 5-3 of the Securities Trading Act, will apply from the time a request for admission to trading on the stock exchange has been made.